Yamauchi, T. et al. Genome-wide CRISPR-Cas9 Screen Identifies Leukemia-Specific
Dependence on a Pre-mRNA Metabolic Pathway Regulated by DCPS. Cancer Cell 33, 386400 e385 (2018). https://doi.org:10.1016/j.ccell.2018.01.012
Colic, M. et al. Identifying chemogenetic interactions from CRISPR screens with drugZ.
Genome Med 11, 52 (2019). https://doi.org:10.1186/s13073-019-0665-3
Mikhailov, V. et al. Bcl-2 prevents Bax oligomerization in the mitochondrial outer membrane. J
Biol Chem 276, 18361-18374 (2001). https://doi.org:10.1074/jbc.M100655200
Martinez Molina, D. et al. Monitoring drug target engagement in cells and tissues using the
cellular thermal shift assay. Science 341, 84-87 (2013).
https://doi.org:10.1126/science.1233606
Fig. 1
Venetoclax
(BCL2 inhibitor)
Cas9-expressing MLL::AF9
mouse AML (mMA9Cas) cells
S63845
(MCL1 inhibitor)
FDR<0.1
Trp53
β-score: Venetoclax
Casp9
GeCKO v2
sgRNA library
DMSO
Bcl2
Bax
Bak1
Ube2j2
-2
Bcl2l1
Mcl1
BCL2i or MCL1i
Trp53
Casp9
Bax
Apaf1
Bak1
Apaf1
Pmaip1
β-score: S63845
Ube2k
Pmaip1
Mcl1
Bcl2
Ube2k
-2
Ube2j2
March5
March5
-4
-4
Bcl2l1
7 days
-4
-2
Assess sgRNA
representation
-2
β-score: DMSO
sgRNA
Venetoclax
-4
β-score: DMSO
Ube2j2
empty vector
100
Ube2k
100
March5
100
100
DMSO
% Crimson
-5
Z-score
Venetoclax
(5 µM)
March5
-10
50
50
50
50
Ube2k
Ube2j2
-15
Genes
Days
Ube2j2
Ube2k
Annexin V (%)
60
March5
p<0.0001
WT
Venetoclax(μM)
60
60
WT
KO
WT
KO
40
WT
KO
p<0.0001
Ube2j2 KO
10
WT
ns
ns
20
20
10
Ube2k KO
10
β-actin
p<0.0001
20
C-casp3
40
40
p<0.001
Venetoclax(μM)
March5 KO
10
10
C-casp3
DMSO
DMSO
VEN
(5 µM)
VEN
(5 µM)
DMSO
Ube2j2 KO
Empty
100
Ube2k KO
HA-Ube2j2
100
β-actin
VEN
(5 µM)
Empty
100
March5 KO
HA-Ube2k
100
Empty
100
Myc-March5
100
% Kusabira Orange
DMSO
Venetoclax
(5 µM)
50
50
50
50
Days
50
50
Fig. 2
WT
sgRNA-Ube2j2
empty vector
100
% Crimson
March5 KO
50
sgRNA-Ube2k
empty vector
sgRNA-Ube2j2
sgRNA-Ube2k
100
100
100
100
100
50
50
50
50
50
DMSO
Venetoclax
(3 µM)
Days
March5C65/68S
100
100
50
50
50
Ub
Days
Ub
MOM
RING
Venetoclax
(3 µM)
50
Ub
Ub
DMSO
Substrate?
100
100
% Kusabira Orange
March5H43W
March5
E2
empty vector
Ube2j2 / 2k
March5
Fig. 3
Venetoclax
(BCL2 inhibitor)
A-1155463
(BCL-XL inhibitor)
100
50
Venetoclax
IC50
WT: N/A
#1: 20.8 nM
#2: 22.7 nM
50
IC50
WT: 4840 nM
#1: 813 nM
#2: 758 nM
WT
March5 KO #1
March5 KO #2
50
100 101 102 103 104 100 101 102 103 104
A-1155463
100
100
% Cell count
% Cell count
100
S63845
(MCL1 inhibitor)
IC50
WT: 10.0 µM
#1: 11.2 µM
#2: 13.1 µM
100 101 102 103 104
100
50
50
50
IC50
NEG: N/A
dTagV-1: 16.5 nM
IC50
NEG: 5210 nM
dTagV-1: 496 nM
100 101 102 103 104
Concentration (nM)
Time (h)
dTagV-1
NEG
Time (h)
dTagV-1
NEG
IC50
NEG: 5650 nM
dTagV-1: 1810 nM
103 104
0 0
10 101 102 103 104
A-1155463 (0.1 µM)
Venetoclax (10 µM)
A-1155463 (0.1 µM)
dTagV-1
NEG
100 101 102
NEG
dTagV-1
Concentration (nM)
Venetoclax (10 µM)
S638845
100
dTagV-1
NEG
Cytosol
Bax
C-casp3
Mitochondria
Gapdh
Cytosol
Cytochrome C
Mitochondria
Venetoclax
% Cell count
Empty vector
50
50
IC50
NEG: 8690 nM
dTagV-1: 1720 nM
% Cell count
50
IC50
NEG:
4290 nM
dTagV-1:
18.6 nM
100 101 102 103 104
% Cell count
100
+Bcl-XL
% Cell count
IC50
NEG: 5080 nM
dTagV-1: 14.2 nM
100 101 102 103 104
50
50
50
IC50
NEG: N/A
dTagV-1: N/A
100 101 102 103 104
IC50
NEG: 6120 nM
dTagV-1:3680 nM
100 101 102 103 104
IC50
NEG: 4610 nM
dTagV-1: 3770 nM
100 101 102 103 104
IC50
NEG: 7780 nM
dTagV-1: 5650 nM
100 101 102 103 104
100
50
IC50
NEG: N/A
dTagV-1:158 nM
100 101 102 103 104
100
50
50
100
50
IC50
NEG: 5950 nM
dTagV-1: 4890 nM
50
100
100
100 101 102 103 104
100
+Mcl1
S638845
100
dTagV-1-NEG
dTagV-1
100 101 102 103 104
100
+Bcl2
A-1155463
100
100
IC50
NEG: 4960 nM
dTagV-1: 2540 nM
100 101 102 103 104
100
50
IC50
NEG: N/A
dTagV-1:5720 nM
100 101 102 103 104
Concentration (nM)
IC50
NEG: 5520 nM
dTagV-1: 2160 nM
0 0
10 101 102 103 104
Fig. 4
March5 KO
March5 KO mMA9Cas
March5
KO
Trp53
FDR<0.05
WT
#1
Ube2j2
KO
#2
#1
Ube2k
KO
#2
#1
March5
KO
#2
M5WT
M5C65/68S
Bax
Apaf1
Noxa
Bak1
Bcl2
Bcl2
Ube2j2
Mcl1
March5
-3
Venetoclax
Ube2k
Bcl-XL
Mcl1
Bcl2l1
7days
-4
-2
Assess sgRNA
representation
Pmaip1
Casp9
Gapdh
β-score: DMSO
Noxa
Cox4
250
Merge
Intensity (a.u.)
200
dTagV-1
-NEG
Noxa
Cox4 (Mitochondria)
DAPI
150
Venetoclax
Intensity (a.u.)
200
150
100
50
dTag -1
NEG
Time (h) 0
Pmaip1 WT
NEG
IC50
WT: 5970 nM
Pmaip1 KO: 6360 nM
March5 KO: 847 nM
DKO: 2760 nM
IC50
WT: N/A
Pmaip1 KO:
N/A
March5 KO:
33.8 nM
DKO:
2310 nM
100 101 102 103 104 100 101 102 103 104
Concentration (nM)
A-1155463 (0.1μM)
Pmaip1 KO
50
Pmaip1 KO
0 1 2 3 4 5 6 7 8 9 10
Distance (µm)
Venetoclax (10μM)
Pmaip1 WT
50
WT
100
100
50
0 1 2 3 4 5 6 7 8 9 10
250
dTagV-1
A-1155463
100
% Cell count
DMSO
β-score: Venetoclax
Brie
sgRNA library
dTag -1
dTag -1
NEG
0 1
Pmaip1 KO
dTagV-1
NEG
C-casp3
Noxa
HA (March5)
Gapdh
IP: α-Noxa
IP: α-Myc
Input
Noxa
IgG
Input
Myc
IgG
Noxa
WT
MG132 -
March5
KO
Ube2k
KO
Ube2j2
KO
(kDa)
75
Myc-M5C65/68S
50
Myc-M5
37
C65/68S
Noxa
Noxa
(TUBE pull down)
25
20
15
10
Noxa (Input)
March5 KO
March5
/Pmaip1 DKO
Fig. 5
IP: anti-Myc (Bcl2)
dTagV-1-NEG
VEN (μM)
IP: anti-Mcl1
dTagV-1
NEG
dTagV-1
IgG 0 0.25 0.5 1.0 5.0 IgG 0 0.25 0.5 1.0 5.0
VEN
IP: anti-Bcl-XL
dTagV-1
NEG
Bax
Bax
Myc-Bcl2
Noxa
Mcl1
IP: anti-Bax
dTagV-1-NEG
VEN (μM) IgG
Bcl-XL
dTagV-1
0.5 1.0 5.0
IgG 0
0.5 1.0 5.0
Myc-Bcl2
Bax
BA
BAX BAX
xa
No
MCL1
BAX
MCL1
BAK
BCL2
Venetoclax
MCL1
MCL1
BAK No
xa
Noxa
Nox
MCL1
BAX
BCL2
xa
MCL1
BCLXL BCLXL
BAX
BAX
BA
No
xa
No
MCL1
MCL1
BCLXL BCLXL
BAK
BAX
BAX
BCL2
Noxa
BCL2
BAX
BCL2
BA
BCL2
BAX
BCLXL BCLXL
BAX
BAX
-intact
BAX
BCL2
BAX
Nox
MARCH5
BCL2
BAX
BAX BAX
BCLXL BCLXL
BAK
BAX
MCL1 MCL1 MCL1
BAX
BAX
BAK
MCL1
MCL1
BAX MCL1 MCL1 MCL1
BAX
BAK
BAX
ox
xa
No
Cell survival
BA
BAX BAX
MARCH5
-depleted
BCL2
BAX
BCL2
BAX
BCL2
BAX
BCL2
BAX
BAX BAX
BAX
BCLXL BCLXL
BAX
BCL2
BCL2
BCLXL BCLXL
BAK
BAX
BCL2
BCL2
BAX
BCLXL BCLXL
BAX
BAX
BCLXL BCLXL
BAK
BAX
Venetoclax
MCL1
BAX
MCL1
Noxa
MCL1
Noxa
MCL1
BAX
MCL1
Noxa
MCL1
BAK
MCL1
BAK
MCL1
Noxa
MCL1
BAX
MCL1
Noxa
MCL1
Noxa
MCL1
BAX
MCL1
Noxa
MCL1
BAK
MCL1
BAK
MCL1
Noxa
BA
BAX
BAX
BA
BAX
Apoptosis
...